NEW YORK (GenomeWeb News) – Bruker said today that a member of the Laukien family sold two million of the company's shares in a block trade, and that CEO Frank Laukien bought 100,000 shares from the same family member in a private transaction.

The life science and environmental research tools maker, which now has a public float of 50.9 million shares, said that the unidentified Laukien family member is not involved in the company's business. The aggregate number of shares sold yesterday amounts to 12.6 percent of the selling shareholder's ownership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.